This article features an interview with Melody (Gaojing) Cao, Product Manager for OptiSite solutions at SLB, discussing her career path from petrochemical engineering to developing digital solutions for asset performance. She explains how OptiSite solutions address key industry challenges like data integration, predictive maintenance, and asset optimization, highlighting their modularity and customer-centric development. Cao also envisions a future for digital production technologies where automation and AI free engineers for higher-value tasks, significantly improving efficiency and safety.

Samsung SDS, the IT service provider arm of Samsung, has secured $820 million (1.22 trillion won) from KKR & Co. through convertible bonds. This marks Samsung SDS's first private equity funding and signals an end to its debt-free policy as the company plans aggressive overseas expansion, including acquisitions, to become a global AI platform. The two companies will also explore acquisition targets in physical AI and stablecoin platforms in the US.

The 35 PGA of America Golf Professionals forming the Corebridge Financial Team are set to compete in the 2026 Senior PGA Championship at The Concession Golf Club from April 16-19. These professionals qualified based on their finishes in the 2025 Senior PGA Professional Championship, with Justin Hicks, PGA, earning the 2025 PGA of America Senior Player of the Year honors. Corebridge Financial sponsors the PGA of America Members in the Association's three Major Championships, highlighting the competitive spirit and dedication of these golf professionals.

Omnicom Health has rebranded FCB Health New York to Olixir New York, a move that follows Omnicom's takeover of IPG and another recent rebranding of DDB Health to Remedy Edge. Linda Bennett and Kathleen Nanda will continue to lead Olixir New York as president and chief creative officer, respectively, building on FCB Health New York's legacy as a top medical marketing agency. The new name combines "elixir" with the "O" from Omnicom and is expected to expand globally after its U.S. launch.

Citigroup reported strong first-quarter 2026 earnings, showing significant progress in its transformation with a 13.1% return on tangible common equity and better-than-expected efficiency ratios. While Morningstar plans to raise its fair value estimate for Citi stock, it believes current share prices already factor in this positive momentum. Investors are now looking ahead to Citigroup's investor day on May 7 for insights into the company's future growth strategy.

Newmont (NEM) has suspended underground operations at its Cadia gold and copper mine in Australia following a 4.5 magnitude earthquake and two aftershocks. This disruption to a significant output mine, coupled with recent insider selling of $5.5 million in shares, may concern investors despite Newmont's strong GF Score™ and financial health. Investors are advised to consider these factors alongside the company's strong long-term growth potential.

Roth Mkm has increased its price target for Occidental Petroleum (NYSE:OXY) from $45.00 to $55.00, while maintaining a "neutral" rating on the stock. This adjustment comes amidst various other analyst re-evaluations, with some firms raising their price targets and ratings, and institutional investors also adjusting their positions in the company. Occidental Petroleum recently reported Q4 earnings per share of $0.31, exceeding consensus estimates, though revenue for the quarter was below expectations.

The Goldman Sachs Group has increased its price target for American Electric Power (NASDAQ:AEP) from $141.00 to $142.00, reiterating a "buy" rating for the utility company. This new target suggests a potential upside of 5.76% from the stock's previous closing price. The article also details recent analyst ratings from other firms, AEP's financial performance, and insider trading activities.

Truist Financial has lowered its price target for Avery Dennison (NYSE:AVY) from $233.00 to $223.00, while maintaining a "buy" rating. Despite this adjustment, other analysts have also issued ratings, contributing to an average "Moderate Buy" rating and a consensus target price of $205.58 for the company. The article also details recent financial performance, insider trading activity, and institutional ownership changes for Avery Dennison.

Abbott Laboratories is being considered as a top oversold blue-chip stock, despite recent legal setbacks where a jury awarded $70 million in damages due to allegations of its infant formula causing harm. Analysts have provided mixed ratings, with Barclays raising its price target while Evercore ISI lowered theirs. Abbott is also expanding its oncology portfolio integration with Flatiron Health.